EP 1087764 A1 20010404 - THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY
Title (en)
THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY
Title (de)
THERAPEUTISCHE KOMBINATIONEN AUS (SELEKTIVE) ESTROGEN-REZEPTOR MODULATOREN (SERM) UND WACHSTUMSHORMONSEKRETIONSFÖRDERER (GHS) ZUR BEHANDLUNG VON MUSKELSKELETT-GEBRECHLICHKEIT
Title (fr)
TRAITEMENT ASSOCIE DE LA FRAGILITE MUSCULO-SQUELETTIQUE A BASE DE MODULATEUR (SELECTIFS) DE RECEPTEURS D'OESTROGENE ET DE SECRETAGOGUES D'HORMONE DE CROISSANCE
Publication
Application
Priority
- IB 9901117 W 19990616
- US 8946998 P 19980616
Abstract (en)
[origin: WO9965486A1] This invention is directed to pharmaceutical combination compositions and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3, 3a, 4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.
IPC 1-7
IPC 8 full level
A61K 31/437 (2006.01); A61K 31/16 (2006.01); A61K 31/40 (2006.01); A61K 31/402 (2006.01); A61K 31/4162 (2006.01); A61K 31/435 (2006.01); A61P 1/02 (2006.01); A61P 19/00 (2006.01); A61P 19/08 (2006.01); A61P 19/10 (2006.01); A61P 43/00 (2006.01)
IPC 8 main group level
CPC (source: EP KR)
A61K 31/435 (2013.01 - EP KR); A61P 1/02 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/08 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
C-Set (source: EP)
Citation (search report)
See references of WO 9965486A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9965486 A1 19991223; AP 9901582 A0 19990630; AR 018869 A1 20011212; AU 4054799 A 20000105; BG 105041 A 20010831; BR 9911324 A 20010403; CA 2335134 A1 19991223; CN 1301160 A 20010627; CO 5070587 A1 20010828; EA 200001186 A1 20010625; EP 1087764 A1 20010404; GT 199900087 A 20001207; HN 1999000097 A 19991103; HR P20000859 A2 20010430; HU P0102505 A2 20011128; HU P0102505 A3 20021228; ID 27599 A 20010412; IL 138630 A0 20011031; IS 5691 A 20001027; JP 2002518326 A 20020625; KR 20010052852 A 20010625; MA 26652 A1 20041220; NO 20006312 D0 20001212; NO 20006312 L 20001212; OA 11505 A 20040507; PA 8475901 A1 20000524; PE 20000646 A1 20000805; PL 344981 A1 20011119; SK 18912000 A3 20011008; TN SN99124 A1 20051110; TR 200003544 T2 20010420; ZA 993975 B 20001215
DOCDB simple family (application)
IB 9901117 W 19990616; AP 9901582 A 19990615; AR P990102848 A 19990615; AU 4054799 A 19990616; BG 10504100 A 20001211; BR 9911324 A 19990616; CA 2335134 A 19990616; CN 99806237 A 19990616; CO 99037622 A 19990616; EA 200001186 A 19990616; EP 99923802 A 19990616; GT 199900087 A 19990616; HN 1999000097 A 19990615; HR P20000859 A 20001214; HU P0102505 A 19990616; ID 20002627 A 19990616; IL 13863099 A 19990616; IS 5691 A 20001027; JP 2000554366 A 19990616; KR 20007014186 A 20001214; MA 25628 A 19990616; NO 20006312 A 20001212; OA 1200000290 A 20001020; PA 8475901 A 19990615; PE 00052899 A 19990615; PL 34498199 A 19990616; SK 18912000 A 19990616; TN SN99124 A 19990616; TR 200003544 T 19990616; ZA 993975 A 19990615